The disease caused by viral pneumonia called severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) declared by the World Health Organization is a global pandemic that the world has witnessed since the last Ebola epidemic, SARS and MERS viruses. Many chemical compounds with antiviral activity are currently undergoing clinical investigation in order to find treatments for SARS-CoV-2 infected patients. On-going drug-drug interaction examinations on new, existing, and repurposed antiviral drugs are yet to provide adequate safety, toxicological, and effective monitoring protocols. This review presents an overview of direct and indirect antiviral drugs, antibiotics, and immune-stimulants used in the management of SARS-CoV-2. It also seeks to outline the recent development of drugs with anti-coronavirus effects; their mono and combination therapy in managing the disease vis-à-vis their biological sources and chemistry. Co-administration of these drugs and their interactions were discussed to provide significant insight into how adequate monitoring of patients towards effective health management could be achieved.

世界卫生组织宣布，由病毒性肺炎引起的疾病，称为严重急性呼吸综合征冠状病毒2型（SARS-CoV-2），是自上次埃博拉疫情、SARS和MERS病毒以来全世界目睹的全球大流行病。许多具有抗病毒活性的化合物目前正在进行临床研究，以便为 SARS-CoV-2 感染患者找到治疗方法。对新的、现有的和重新利用的抗病毒药物正在进行的药物相互作用检查尚未提供足够的安全性、毒理学和有效的监测方案。本综述概述了用于治疗 SARS-CoV-2 的直接和间接抗病毒药物、抗生素和免疫刺激剂。它还试图概述具有抗冠状病毒作用的药物的最新开发情况；他们在控制疾病方面的单一和联合疗法相对于其生物来源和化学性质。讨论了这些药物的共同给药及其相互作用，以深入了解如何对患者进行充分监测以实现有效的健康管理。